U.S. markets open in 6 hours 31 minutes
  • S&P Futures

    4,536.50
    -5.25 (-0.12%)
     
  • Dow Futures

    35,480.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    15,404.75
    -74.00 (-0.48%)
     
  • Russell 2000 Futures

    2,299.10
    +5.00 (+0.22%)
     
  • Crude Oil

    82.05
    -0.45 (-0.55%)
     
  • Gold

    1,794.20
    +12.30 (+0.69%)
     
  • Silver

    24.38
    +0.21 (+0.87%)
     
  • dólar/euro

    1.1641
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.6760
    0.0000 (0.00%)
     
  • Vix

    15.01
    -0.48 (-3.10%)
     
  • dólar/libra

    1.3796
    0.0000 (-0.00%)
     
  • yen/dólar

    113.9600
    -0.0280 (-0.02%)
     
  • BTC-USD

    62,723.48
    -1,845.08 (-2.86%)
     
  • CMC Crypto 200

    1,491.96
    -42.69 (-2.78%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

MiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 3:30 PM Eastern Time.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.

Date: Wednesday, February 17, 2021
Time: 3:30 PM ET
Webcast: https://wsw.com/webcast/btig3/mdxg/1732752

A replay of the webcast will be available for approximately 90 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.

About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@mimedx.com